Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android


Chief Complaint

Weakness and diarrhea after completing antibiotic therapy with levofloxacin for pyelonephritis

History of Present Illness

On day five of the current hospitalization LD complains of severe abdominal pain. She has received three days of fidaxomicin for Clostridioides difficile infection (CDI). The team noted absent bowel sounds and sent the patient for imaging. Abdominal x-ray reveals ileus. The patient’s home medications have not been restarted yet this admission.

Student Work-Up

|Download (.pdf)|Print

Missing Information?


Patient Database

Drug Therapy Problems

Care Plan (by Problem)


  1. What are the risk factors for LD developing CDI?

    Hint: See Inflammatory Gastrointestinal Infections in PPP

  2. How would you categorize CDI based on LD’s signs and symptoms?

    Hint: See Inflammatory Gastrointestinal Infections in PPP

  3. What is the recommended therapy for initial episodes of CDI?

    Hint: See Inflammatory Gastrointestinal Infections in PPP

  4. What are limitations to the use of fidaxomicin in this patient?

    Hint: See Inflammatory Gastrointestinal Infections in PPP

  5. What therapeutic changes do you recommend for LD?

    Hint: See Inflammatory Gastrointestinal Infections in PPP


What FDA-indicated therapy would provide secondary prevention of CDI for this patient?


Global Perspective

Recent updates to the management of C. difficile infection have been published both in the United States and Europe. Major changes include recommendations regarding first-line therapy for initial and recurrent CDI. The place in therapy of fidaxomicin is defined. Management of severe or fulminant infection remains the same. Additionally, bezlotoxumab, a monoclonal antibody that binds Clostridioides difficile toxin B, has been approved to decrease the risk of CDI recurrence. Fidaxomicin and bezlotoxumab are costly agents, this along with their benefits need to be considered when recommending therapy.

Key References

1. +
Johnson  S, Lavergne  V, Skinner  AM, Gonzales-Luna  AJ, Garey  KW, Kelly  CP, Wilcox  MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Sep 7;73(5):e1029–e1044.  [PubMed: 34164674]

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.